Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Breakthrough infection
Omicron
SARS-CoV-2
Severity
Vaccine
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
27
09
2022
revised:
23
12
2022
accepted:
24
12
2022
medline:
28
4
2023
pubmed:
2
1
2023
entrez:
1
1
2023
Statut:
ppublish
Résumé
The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. Among 1215 patients (median age, 73.0 years; interquartile range, 57.0-84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32-0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26-0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25-0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37-0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12-0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38-0.67]), independent of age, comorbidities, and vaccination status. Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics.
Identifiants
pubmed: 36587737
pii: S1198-743X(22)00644-9
doi: 10.1016/j.cmi.2022.12.020
pmc: PMC9798780
pii:
doi:
Substances chimiques
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
642-650Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Clin Microbiol Infect. 2022 Dec;28(12):1629-1635
pubmed: 35779764
Front Public Health. 2022 May 02;10:875022
pubmed: 35586013
Euro Surveill. 2022 Mar;27(9):
pubmed: 35241215
EClinicalMedicine. 2022 Jun;48:101455
pubmed: 35611065
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Cell. 2022 Mar 3;185(5):860-871.e13
pubmed: 35120603
Vaccines (Basel). 2022 Aug 16;10(8):
pubmed: 36016216
Clin Infect Dis. 2023 Feb 8;76(3):e234-e239
pubmed: 35724127
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):132-138
pubmed: 35085223
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
N Engl J Med. 2022 Aug 4;387(5):468-470
pubmed: 35857646
J Transl Med. 2022 Apr 15;20(1):176
pubmed: 35428263
Nature. 2021 Dec;600(7888):204-207
pubmed: 34876665
Lancet. 2022 Jan 1;399(10319):25-35
pubmed: 34942103
J Intern Med. 2022 Jul;292(1):127-135
pubmed: 35194861
Oxf Open Immunol. 2022 Jun 20;3(1):iqac003
pubmed: 35872966
Euro Surveill. 2021 Oct;26(41):
pubmed: 34651577
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119
pubmed: 35858386
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Kidney Int. 2022 Feb;101(2):390-402
pubmed: 34856313